Randomized trial · people

Exenatide did not cut heavy drinking days in alcohol use disorder

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In this trial, weekly exenatide plus therapy did not reduce heavy drinking overall, though it changed brain responses to alcohol cues and showed a signal in people with obesity.

Kind
Randomized trial
Studied in
People
Number studied
127
Published
2022
Journal
JCI Insight

What they tested

The team tested whether weekly exenatide lowers the number of heavy drinking days in people seeking treatment for alcohol use disorder.

How the study was done

A randomized, double-blind, placebo-controlled trial in 127 patients with alcohol use disorder. They received exenatide 2 mg or placebo (a dummy shot) under the skin once weekly for 26 weeks, on top of standard cognitive-behavioral therapy (talk therapy), and a subgroup had brain scans.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking exenatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

The main outcome, heavy drinking days, did not fall by a statistically significant amount with exenatide versus placebo. On fMRI brain scans, people on exenatide showed significantly weaker reactions to alcohol cues in the ventral striatum and septal area, regions linked to reward and addiction. SPECT scans showed less dopamine transporter availability with exenatide than with placebo. In an exploratory look at patients with obesity (BMI > 30 kg/m2), those on exenatide had significantly fewer heavy drinking days and drank less alcohol overall, and side effects were mostly in the gut.

What it doesn’t show

The trial missed its main goal in the full group. The brain scans covered only a subgroup, and the benefit in patients with obesity came from an exploratory analysis, so it is a lead rather than a confirmed result.

The paper

Klausen et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022.

The compound

More studies on Exenatide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking exenatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo